Skip to main content

Advertisement

SpringerLink
Log in

Osteosarcoma treatment: state of the art

  • NON-THEMATIC REVIEW
  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Osteosarcoma (OS) is a class of cancer originating from bone, mainly afflicting children or young adults. It is the second highest cause of cancer-related death in these age groups, mainly due to development of often fatal metastasis, usually in the lungs. Survival for these patients is poor despite the aggressive use of surgery, chemotherapy, and/or radiotherapy. Thus, new effective drugs and other forms of therapy are needed. This article reviews the biology and the state of the art management of OS. New experimental drugs and potential therapies targeting molecular pathways of OS are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Article Open access 08 December 2016

Brock A. Lindsey, Justin E. Markel & Eugenie S. Kleinerman

References

  1. Unni, K. K. (1996). Dahlin’s bone tumors: General aspects and data on 11,087 cases. Philadelphia: Lippincott-Raven.

    Google Scholar 

  2. Buecker, P. J., Gebhardt, M. C., Weber, K. (2005). Osteosarcoma. Liddy Shriver Sarcoma Initiative. http://sarcomahelp.org/Newsletters/V02N01/Osteosarcoma/osteosarcoma.htm. Accessed 30 September 2008.

  3. The-Cancer-Council-Victoria. (2006). Osteosarcoma and flouride. http://www.ada.org.au/app_cmslib/media/lib/0703/m50781_v1_osteosarcomaandfluoride.pdf. Accessed 20 June 2008.

  4. Longhi, A., Errani, C., De Paolis, M., Mercuri, M., & Bacci, G. (2006). Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treatment Reviews, 32, 423–436.

    Article  PubMed  Google Scholar 

  5. Quan, G. M. Y., Ojaimi, J., Nadesapillai, W. A. P., Zhou, H., & Choong, P. F. M. (2002). Resistance of epiphyseal cartilage to invasion by osteosarcoma of antiangiogenic factors. Pathobiology, 70, 361–367.

    Article  PubMed  CAS  Google Scholar 

  6. Whelan, J. (2005). Advances in osteosarcoma. In T. O. B. Eden, et al. (Eds.), Cancer and the adolescent (pp. 113–120). Malden: Blackwell.

    Chapter  Google Scholar 

  7. Dass, C. R., Ek, E. T., Contreras, K. G., & Choong, P. F. (2006). A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clinical and Experimental Metastasis, 23, 367–380.

    PubMed  Google Scholar 

  8. Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004). Biology and therapeutic advances for pediatric osteosarcoma. The Oncologist, 9, 422–441.

    Article  PubMed  Google Scholar 

  9. Clark, J. C. M., Dass, C. R., & Choong, P. F. M. (2007). A review of clinical and molecular prognostic factors in osteosarcoma. Journal of Cancer Research Clinical Oncology, 134, 281–297.

    Article  CAS  Google Scholar 

  10. Rytting, M., Pearson, P., & Raymond, A. K. (2000). Osteosarcoma in preadolescent patients. Clinical Orthopaedics, 373, 39–50.

    Article  Google Scholar 

  11. Fraumeni, J. F. (1967). Stature and malignant tumors of bones in childhood and adolescence. Cancer, 20, 967–973.

    Article  PubMed  Google Scholar 

  12. Grimer, R. J. (2005). Osteosarcoma and surgery. In T. O. B. Eden, et al. (Eds.), Cancer and the adolescent (pp. 121–132). Malden: Blackwell.

    Chapter  Google Scholar 

  13. Withrow, S. J., Powers, B. E., Straw, R. C., & Wilkins, R. M. (1991). Comparative aspects of osteosarcoma. Dog versus man. Clinical Orthopaedics and Related Research, 270, 159–168.

    PubMed  Google Scholar 

  14. Tjalma, R. A. (1966). Canine bone sarcoma: estimation of relative risk as a function of body size. Journal of the National Cancer Institute, 36, 1137–1150.

    PubMed  CAS  Google Scholar 

  15. Cotterill, S. J., Wright, C. M., Pearce, M. S., & Craft, A. W. (2004). Stature of young people with malignant bone tumors. Pediatric Blood and Cancer, 42, 59–63.

    Article  PubMed  Google Scholar 

  16. Gelberg, K. H., Fitzgerald, E. F., Hwang, S., & Dubrow, R. (1997). Growth and development and other risk for osteosarcoma in children and young adults. International Journal of Epidemiology, 26, 272–278.

    Article  PubMed  CAS  Google Scholar 

  17. Longhi, A., Pasini, A., Cicognani, A., Baronio, F., Pellacani, A., & Baldini, N. (2005). Height as a risk factor for osteosarcoma. Journal of pediatric hematology/oncology, 27, 314–318.

    Article  PubMed  Google Scholar 

  18. Longhi, A., Barbieri, E., & FAbbri, N. (2003). Radiation-induced osteosarcoma arising 20 years after the treatment of Ewing’s sarcoma. Tumorigenesis, 89, 569–572.

    Google Scholar 

  19. Picci, P. (2007). Osteosarcoma (Osteogenic sarcoma). Orphanet Journal of Rare Diseases, 2, 1–4.

    Article  Google Scholar 

  20. Fuschs, B., & Pritchard, D. J. (2002). Etiology of osteosarcoma. Clinical orthopaedics, 397, 40–52.

    Article  Google Scholar 

  21. Wang, L. L., Gannavaparu, A., & Kozinets, C. A. (2003). Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. Journal of the National Cancer Institute, 95, 669–674.

    PubMed  CAS  Google Scholar 

  22. Finkel, M. P., Biskis, B. O., & Jinkins, P. B. (1966). Virus induction of osteosarcomas in mice. Science, 151, 698–701.

    Article  PubMed  CAS  Google Scholar 

  23. Fuchs, B., & Pritchard, D. J. (2002). Etiology of osteosarcoma. Clinical Orthopaedics, 397, 40–52.

    Article  Google Scholar 

  24. Kakar, S., Mihalov, M., Chachlani, N. A., Ghosh, L., & Johnstone, H. (2000). Correlation of c-fos, p53, and PCNA expression with treatment outcome in osteosarcoma. Journal of surgical oncology, 73, 125–126.

    Article  PubMed  CAS  Google Scholar 

  25. Mendoza, S. M., Konishi, T., & Miller, C. W. (1998). Integration of SV40 in human osteosarcoma DNA. Oncogene, 17, 2457–2462.

    Article  PubMed  CAS  Google Scholar 

  26. Engels, E. A. (2005). Cancer risk associated with receipt of vaccines contaminated with simian virus 40: epidemiologic research. Expert Review of Vaccines, 4, 197–206.

    Article  PubMed  Google Scholar 

  27. Franchi, A., Arganini, L., & Baroni, G. (1998). Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high grade osteosarcomas. Journal of pathology, 185, 284–289.

    Article  PubMed  CAS  Google Scholar 

  28. Huvos, A. (1991). Bone tumors: Diagnosis, treatment and prognosis. Philadelphia: Saunders.

    Google Scholar 

  29. Skubitz, K. M., & D’Adamo, D. R. (2007). Sarcoma. Mayo Clinic Proceedings, 82, 1409–1432.

    Article  PubMed  CAS  Google Scholar 

  30. Wittig, J. C., Bickels, J., Priebat, D., Jelinek, J., Kellar-Graney, K., Shmookler, B., et al. (2002). Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. American Family Physician, 65, 1123–1132.

    PubMed  Google Scholar 

  31. Link, M. P., Goorin, A. M., Horowitz, M., Meyer, W. H., Belasco, J., Baker, A., et al. (1991). Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study. Clinical Orthopaedics and Related Research, 270, 8–14.

    PubMed  Google Scholar 

  32. Hannisdal, E., Solheim, O. P., Theodorsen, L., & Host, H. (1990). Alterations of blood analyses at relapse of osteosarcoma and Ewing’s sarcoma. Acta oncologica, 29, 585–587.

    Article  PubMed  CAS  Google Scholar 

  33. Bacci, G., Longhi, A., Ferrari, S., Lari, S., Manfrini, M., Donati, D., et al. (2002). Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncology reports, 9, 171–175.

    PubMed  Google Scholar 

  34. Bacci, G., Longhi, A., Ferrari, S., Briccoli, A., Donati, D., Paolis, M. D., et al. (2004). Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: Experience at Rizzoli on 1421. Tumorigenesis, 90, 478–484.

    Google Scholar 

  35. Aisen, A. M., Martel, W., Braunstein, E. M., McMillin, K. I., Phillips, W. A., & Kling, T. F. (1986). MRI and CT evaluation of primary bone and soft-tissue tumors. AJR. American Journal of Roentgenology, 146, 749–756.

    PubMed  CAS  Google Scholar 

  36. Mankin, H. J., Mankin, C. J., & Simon, M. A. (1996). The hazards of the biopsy, revisited: members of the Musculoskeletal Tumor Society. The Journal of bone and joint surgery, 78, 656–663.

    PubMed  CAS  Google Scholar 

  37. Dahlin, D. C. (1978). Osteosarcoma of bone and a consideration of prognostic variables. Cancer Treatment Reports, 62, 189–192.

    PubMed  CAS  Google Scholar 

  38. Ozaki, T., Flege, S., Kevric, M., Lindner, N., Masas, R., Delling, G. S. R., et al. (2003). Osteosarcoma of the pelvic: experience of the Cooperative Osteosarcoma Study Group. Journal of Clinical Oncology, 21, 334–341.

    Article  PubMed  Google Scholar 

  39. Ozaki, T., Flege, S., Liljenqvist, U., Hillmann, A., Delling, G. S. R., Salzer-Kuntschik, M., et al. (2002). Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. Cancer, 94, 1069–1077.

    Article  PubMed  Google Scholar 

  40. Magishi, K., Yoshida, H., Izumi, Y., Ishikawa, N., & Kubota, H. (2004). Primary osteosarcoma of the lung: report of a case. Surgery Today, 34, 150–152.

    Article  PubMed  Google Scholar 

  41. Bieling, P., Rehan, N., Winkler, P., Helmke, K., Maas, R., Fuchs, N., et al. (1996). Tumor size and prgonosis in sggressively treated osteosarcoma. Journal of Clinical Oncology, 14, 848–858.

    PubMed  CAS  Google Scholar 

  42. Wolf, R. E., & Enneking, W. F. (1996). The staging and surgery of musculoskeletal neoplasms. The Orthopedic clinics of North America, 27, 473–481.

    PubMed  CAS  Google Scholar 

  43. Greene, F. L., Page, D. L., Fleming, I. D., Fritz, A., Balch, C. M., Haller, D. G., et al. (2002). AJCC cancer staging manual (6th). New York: Springer.

    Book  Google Scholar 

  44. Meyers, P. A., & Gorlick, R. (1997). Osteosarcoma. Pediatric clinics of North America, 44, 973–989.

    Article  PubMed  CAS  Google Scholar 

  45. Bacci, G., Longhi, A., Fagioli, F., Briccoli, A., Versari, M., & Picci, P. (2005). Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 years experience at Rizzoli Institute, Italy. European Journal of Cancer, 41, 2836–2845.

    Article  PubMed  CAS  Google Scholar 

  46. Patel, S. J., Lynch, J. W. J., Johnson, T., Carroll, R. R., Schumacher, C. R. N., Spanier, S., & Scarborough, M. (2002). Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. American Journal of Clinical Oncology, 25, 489–495.

    Article  PubMed  Google Scholar 

  47. Halperin, E. C. (2005). Osteosarcoma. In E. C. Halperin, et al. (Eds.), Pediatric Radiation Oncology (pp. 291–318). Philadelphia: Williams & Wilkins.

    Google Scholar 

  48. Ferguson, W. S., & Goorin, A. M. (2001). Current treatment of osteosarcoma. Cancer Investigation, 19, 292–315.

    Article  PubMed  CAS  Google Scholar 

  49. Ozaki, I., Flege, S., Lijenqvist, U., Hillmann, A., Delling, G., Salzer-Kuntschik, M., et al. (2002). Osteosarcoma of the spine: experience of the Cooperative Osteosarcom Study Group. Cancer, 94, 1069–1077.

    Article  PubMed  Google Scholar 

  50. Ferrari, S., Smeland, S., Mercuri, M., Bertoni, F., Longhi, A., Ruggieri, P., et al. (2005). Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. Journal of Clinical Oncology, 23, 8845–8852.

    Article  PubMed  Google Scholar 

  51. Jaff, N., Carrasco, H., Raymond, K., Ayala, A., & Eftekhari, F. (2003). Cancure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery. Cancer, 95, 2202–2210.

    Article  Google Scholar 

  52. Lee, E. S. (1971). Treatment of bone sarcoma. Proceedings of the Royal Society of Medicine, 64, 1179–1181.

    PubMed  CAS  Google Scholar 

  53. Philips, T. L., & Sheline, G. E. (1969). Radiation therapy of malignant bone tumors. Radiology, 92, 1537–1545.

    Google Scholar 

  54. Machak, G. N., Tkachev, S. I., Solovyev, Y. N., Sinyukov, P. A., Ivanov, S. M., Kochergina, N. V., et al. (2003). Neoadjuvant chemotherapy and local radiotherapy for high grade osteosarcoma of the extremities. Mayo Clinic Proceedings, 78, 147–155.

    Article  PubMed  Google Scholar 

  55. Yamamoto, T., Akisue, T., Marui, T., Nagira, K., & Kurosaka, M. (2002). Osteosarcoma of the distal radius treated by introperative extracorporeal irradiation. Journal of the Hand Surgery, 27, 160–164.

    Google Scholar 

  56. Hong, A., Stevens, G., Stalley, P., Pendlebury, S., Ahern, V., Ralston, A., et al. (2001). Extracorporeal irradiation for malignant bone tumors. International Journal of Radiation Oncology, Biology, Physics, 50(2), 441–447.

    Article  PubMed  CAS  Google Scholar 

  57. Araki, N., Myoui, A., Kuratsu, S., Hashimoto, N., Inoue, T., Kudawara, I., et al. (1999). Intraoperative extracorporeal autogenous irradiated bone graft in tumor surgery. Clinical Orthopaedics, 368, 196–206.

    Article  Google Scholar 

  58. Gilchrist, G. S., Pritchard, D. J., & Dahlin, D. C. (1981). Management of osteogenic sarcoma: a perspective based on the Mayo Clinic experience. National Cancer Institute Monograph, 56, 193–199.

    PubMed  Google Scholar 

  59. Giritsky, A. S., Etucubanas, E., & Mark, J. B. (1978). Pulmonary resection in children with metastaic osteogenic sarcoma: improved survival with surgery, chemotherapy, and irradiation. The Journal of Thoracic and Cardiovascular Surgery, 75, 354–362.

    PubMed  CAS  Google Scholar 

  60. Weichselbaum, R. R., Cassady, J. R., & Jaffe, N. (1977). Preliminary results of aggressive multimodality therapy for metastatic osteosarcoma. Cancer, 40, 78–83.

    Article  PubMed  CAS  Google Scholar 

  61. Picci, P., Bacci, G., Campanacci, M., Gasparini, M., Pilotti, S., Cerasoli, S., et al. (1985). Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Cancer, 56, 1515–1521.

    Article  PubMed  CAS  Google Scholar 

  62. Eilber, F., Giuliano, A., Eckardt, J., Patterson, K., Moseley, S., & Goodnight, J. (1987). Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. Journal of Cancer and Clinical Oncology, 5, 21–26.

    CAS  Google Scholar 

  63. Link, M. P., Goorin, A. M., Horowitz, M., Meyer, W. H., Belasco, J., Baker, A., et al. (1991). Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clinical orthopaedics, 270, 8–14.

    Google Scholar 

  64. Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., et al. (1982). Preoperative chemotherapy of osteosarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to the preoperative therapy. Cancer, 49, 1221–1230.

    Article  PubMed  CAS  Google Scholar 

  65. Hudson, M., Jaffe, M. R., Jaffe, N., Ayala, A., Raymond, A. K., Carrasco, H., et al. (1990). Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. Journal of Clinical Oncology, 12, 1988–1997.

    Google Scholar 

  66. Provisor, A. J., Ettinger, L. J., Nachman, J. B., Krailo, M. D., Makley, J. T., Yunis, E. J., et al. (1997). Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. Journal of Clinical Oncology, 15, 76–84.

    PubMed  CAS  Google Scholar 

  67. Man, T.-K., Chintagumpala, M., Visvanathan, J., Shen, J., Perlaky, L., Hicks, J., et al. (2005). Expression Profiles of Osteosarcoma That Can Predict Response to Chemotherapy. Cancer Research, 65, 8142–8150.

    Article  PubMed  CAS  Google Scholar 

  68. Souhami, R. L., Craft, A. W., Van der Eijken, J. W., Nooij, M., Spooner, D., Bramwell, V. H., et al. (1997). Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet, 350, 911–917.

    Article  PubMed  CAS  Google Scholar 

  69. Ferrari, S., & Palmerini, E. (2007). Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Current Opinion in Oncology, 19, 341–346.

    Article  PubMed  CAS  Google Scholar 

  70. Fuchs, N., Bielack, S. S., Epler, D., Biding, P., Delling, G., Körholz, D., et al. (1998). Long-term results of the co-operative German-Austrian-Swiss Osteosarcoma Study Group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Annals of Oncology, 9, 893–899.

    Article  PubMed  CAS  Google Scholar 

  71. Petrilli, A. S., de Camargo, B., Filho, V. O., Bruniera, P., Brunetto, A. L., Jesus-Garcia, R., et al. (2006). Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. Journal of Clinical Oncology, 24, 1161–1168.

    Article  PubMed  Google Scholar 

  72. Meyers, P. A., Schwartz, C. L., Krailo, M. D., Kleinerman, E. S., Betcher, D., Bernstein, M. L., et al. (2005). Osteosarcoma: a randomized prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin and high-dose methotrexate. Journal of Clinical Oncology, 23, 2004–2011.

    Article  PubMed  CAS  Google Scholar 

  73. Eselgrim, M., Grunert, H., Kuhne, T., Zoubek, A., Kevric, M., Bürger, H., et al. (2006). Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trial. Pediatric Blood and Cancer, 47, 42–50.

    Article  PubMed  Google Scholar 

  74. Lewis, I. J., Weeden, S., Machin, D., Stark, D., & Craft, A. W. (2000). Received dose and dose intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. Journal of Clinical Oncology, 18, 4028–4037.

    PubMed  CAS  Google Scholar 

  75. Daw, N. C., Billups, C. A., Rodriguez-Galindo, C., McCarville, M. B., Rao, B. N., Cain, A. M., et al. (2006). Metastatic osteosarcoma. Cancer, 106, 403–412.

    Article  PubMed  Google Scholar 

  76. Bacci, G., Fabbri, N., Balladelli, A., Forni, C., Palmerini, E., & Picci, P. (2006). Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients. Journal of Bone and Joint Surgery American, 88, 1071–1075.

    Article  CAS  Google Scholar 

  77. Kager, L., Zoubek, A., Kastner, U., Kempf-Bielack, B., Potratz, J., Kotz, R., et al. (2006). Skip metastases in osteosarcoma : Experience of The Cooperative Osteosarcoma Study Group. Journal of Clinical Oncology, 24, 1535–1541.

    Article  PubMed  Google Scholar 

  78. Ek, E. T. H., Dass, C. R., Contreras, K. G., & Choong, P. F. M. (2007). Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Therapy, 14, 616–626.

    Article  PubMed  CAS  Google Scholar 

  79. Okuno, S. (2006). Mammalian target of rapamycin inhibitors in sarcomas. Current Opinion in Oncology, 18, 360–362.

    Article  PubMed  CAS  Google Scholar 

  80. Kubo, T., Shimose, S., Matsuo, T., Tanaka, K., Yasunaga, Y., Sakai, A., et al. (2006). Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. Journal of Orthopaedic Research, 24, 1138–1144.

    Article  PubMed  CAS  Google Scholar 

  81. Murayama, T., Kawasoe, Y., Yamashita, Y., Ueno, Y., Minami, S., Yokouchi, M., et al. (2008). Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines. Anticancer Reseach, 28, 2147–2154.

    CAS  Google Scholar 

  82. Kubista, B., Trieb, K., Sevelda, F., Toma, C., Arrich, F., Heffeter, P., et al. (2006). Anticancer effects of zoledronic acid against human osteosarcoma cells. Journal of Orthopaedic Research, 24, 1145–1152.

    Article  PubMed  CAS  Google Scholar 

  83. Horie, N., Murata, H., Kimura, S., Takeshita, H., Sakabe, T., Matsui, T., et al. (2007). Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. British Journal of Cancer, 96, 255–261.

    Article  PubMed  CAS  Google Scholar 

  84. Benassi, M., Chiechi, A., Ponticelli, F., Pazzaglia, L., Gamberi, G., Zanella, L., et al. (2006). Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Letters, 250, 194–205.

    Article  PubMed  CAS  Google Scholar 

  85. Tomlin, J. L., Pead, M. J., & Muir, P. (2000). Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. The Veterinary Record, 147, 129–132.

    PubMed  CAS  Google Scholar 

  86. Kotz, R., Plattner, E., Ramach, W., Flener, R., & Bodo, G. (1982). Interferon/controlled study in 3-year survival of patients with recurrent osteosarcoma. Arzneimittelforschung, 32, 446–448.

    PubMed  CAS  Google Scholar 

  87. Müller, C. R., Smeland, S., Bauer, H. C., Saeter, G., & Strander, H. (2005). Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncologica, 44, 475–480.

    Article  PubMed  CAS  Google Scholar 

  88. Strander, H., Aparisi, T., Blomgren, H., Broström, L. A., Cantell, K., Einhorn, S., et al. (1982). Adjuvant interferon treatment of human osteosarcoma. Recent Results Cancer Research, 80, 103–107.

    CAS  Google Scholar 

  89. Strander, H., Bauer, H. C., Brosjö, O., Kreicbergs, A., Lindholm, J., Nilsonne, U., et al. (1993). Adjuvant interferon treatment in human osteosarcoma. Cancer Treatment and Research, 62, 29–32.

    PubMed  CAS  Google Scholar 

  90. Winkler, K., Beron, G., Kotz, R., Salzer-Kuntschik, M., Beck, J., Beck, W., et al. (2004). Adjuvant chemotherapy in osteosarcoma—Effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Journal of Cancer Research and Clinical Oncology, 106, 1–7.

    Article  Google Scholar 

  91. Stanton, G. J., Weigent, D. A., Fleischmann, W. R. J., Dianzani, F., & Baron, S. (1987). Interferon review. Investigative Radiology, 22, 259–273.

    Article  PubMed  CAS  Google Scholar 

  92. Jonasch, E., & Haluska, F. G. (2001). Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities. Oncologist, 1, 34–55.

    Article  Google Scholar 

  93. Strander, H. (1989). The action of interferon on virus-associated human neoplasms. Cancer Surveys, 8, 755–792.

    PubMed  CAS  Google Scholar 

  94. Glasgow, L. A., Crane, J. L. Jr., Kern, E. R., & Youngner, J. S. (1978). Antitumor activity of interferon angainst murine osteogenic sarcoma in vitro and in vivo. Cancer Treatment Reports, 62, 1881–1888.

    PubMed  CAS  Google Scholar 

  95. Glasgow, L. A., & Kern, E. R. (1981). Effect of interferon administration on pulmonary osteogenic sarcomas in an experimental murine model. Journal of the National Cancer Institute, 67, 207–212.

    PubMed  CAS  Google Scholar 

  96. Jia, S. F., An, T., Worth, L., & Kleinerman, E. S. (1999). Interferon-alpha Enhances the Sensitivity of Human Osteosarcoma Cells to Etoposide. Journal of Interferon and Cytokine Research, 19, 617–624.

    Article  PubMed  CAS  Google Scholar 

  97. Yuan, X.-w., Zhu, X.-f., Huang, X.-f., Sheng, P.-y., He, A.-s., Yang, Z.-b., et al. (2007). Interferon-a enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis. Acta Pharmacologica Sinica, 28, 1835–1841.

    Article  PubMed  CAS  Google Scholar 

  98. Inaba, H., Glibetic, M., Buck, S., Ravindranath, Y., & Kaplan, J. (2004). Interferon-alpha sensitizes osteosarcoma cells to Fas-induced apoptosis by up-regulating Fas receptors and caspase-8. Pediatrica Blood Cancer, 43, 729–736.

    Article  Google Scholar 

  99. Waldmann, T. A. (2006). The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nature reviews. Immunology, 6, 595–601.

    Article  PubMed  CAS  Google Scholar 

  100. Waldmann, T. A., & Tagaya, Y. (1999). The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annual Review of Immunology, 17, 19–49.

    Article  PubMed  CAS  Google Scholar 

  101. Luksch, R., Perotti, D., Cefalo, G., Gambacorti Passerini, C., Massimino, M., Spreafico, F., et al. (2003). Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumorigenesis, 89, 263–268.

    CAS  Google Scholar 

  102. Schwartz, Y., Avraham, R., Benish, M., Rosenne, E., & Ben-Eliyahu, S. (2008). Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells. Breast Cancer Research and Treatment, 107, 211–223.

    Article  PubMed  CAS  Google Scholar 

  103. Nardin, A., Lefebvre, M. L., Labroquere, K., Faure, O., & Abastado, J. P. (2006). Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Current Cancer Drug Targets, 6, 123–133.

    Article  PubMed  CAS  Google Scholar 

  104. Chawla, S. P., Tolcher, A. W., Staddon, A. P., Schuetze, S. M., D’Amato, G. Z., Blay, J. Y., et al. (2006). Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas (Abstract). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, Part I., 24 (June 20 Supplement), Abstract 9505.

  105. Quan, G. M. Y., & Choong, P. F. M. (2006). Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Review, 25, 707–713.

    Article  Google Scholar 

  106. Folkman, J. (2004). Endogenous angiogenesis inhibitors. Acta pathologica, microbiologica, immunologica Scandinavica, 112, 496–507.

    CAS  Google Scholar 

  107. Tjin Tham Sjin, R. M., Naspinski, J., Birsner, A. E., Li, C., Chan, R., Lo, K. M., et al. (2006). Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Therapy, 13, 619–627.

    Article  PubMed  CAS  Google Scholar 

  108. Mohammed, R. A., Green, A., El-Shikh, S., Paish, E. C., Ellis, I. O., & Martin, S. G. (2007). Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. British Journal of Cancer, 96, 1092–1100.

    Article  PubMed  CAS  Google Scholar 

  109. Kaya, M., Wada, T., Akatsuka, T., Kawaguchi, S., Nagoya, S., Shindoh, M., et al. (2000). Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clinical Cancer Research, 6, 572–577.

    PubMed  CAS  Google Scholar 

  110. Hara, H., Akisue, T., Fujimoto, T., Imabori, M., Kawamoto, T., Kuroda, R., et al. (2006). Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. Anticancer Research, 26, 4307–4311.

    PubMed  CAS  Google Scholar 

  111. Mantadakis, E., Kim, G., Reisch, J., McHard, K., Maale, G., Leavey, P. J., et al. (2001). Lack of prognostic significance of intratumoral angiogenesis in non metastatic osteosarcoma. Journal of Pediatric Hematology/Oncology, 23, 286–289.

    Article  PubMed  CAS  Google Scholar 

  112. Ek, E. T. H., Ojaimi, J., Kitagawa, Y., & Choong, P. F. M. (2006). Does the degree of intratumoral microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncology Reports, 16, 17–23.

    PubMed  CAS  Google Scholar 

  113. Kreuter, M., Bieker, R., Bielack, S. S., Auras, T., Buerger, H., Gosheger, G., et al. (2004). Prognostic relevance of increased angiogenesis in osteosarcoma. Clinical Cancer Research, 10, 8531–8537.

    Article  PubMed  Google Scholar 

  114. Dawson, D. W., Volpert, O. V., Gillis, P., Crawford, S. E., Xu, H., & Benedict, W. (1999). Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science, 285, 245–248.

    Article  PubMed  CAS  Google Scholar 

  115. Volpert, O. V., Zaichuk, T., Zhou, W., Reiher, F., Ferguson, T. A., & Stuart, P. M. (2002). Inducer-stimulated Fas targets activates endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nature Medicine, 8, 349–357.

    Article  PubMed  CAS  Google Scholar 

  116. Cai, J., Jiang, W. G., Grant, M. B., & Boulton, M. (2006). Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of VEGFR-1. Journal of biological chemistry, 281, 3604–3613.

    Article  PubMed  CAS  Google Scholar 

  117. Pignolo, R. J., Francis, M. K., Rotenberg, M. O., & Cristofalo, V. J. (2003). Putative role for EPC-1/PEDF in the growth arrest of human diploid fibroblasts. Journal of cellular physiology, 195, 12–20.

    Article  PubMed  CAS  Google Scholar 

  118. Abe, R., Shimizu, T., Yamagishi, S., Shibaki, A., Amano, S., & Inagaki, Y. (2004). Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. The American Journal of Pathology, 164, 1225–1232.

    PubMed  CAS  Google Scholar 

  119. Foukas, A. F., Deshmukh, N. S., Grimer, R. J., Mangham, D. C., Mangos, E. G., & Taylor, S. (2002). Stage-IIB osteosarcoma around the knee. A study of MMP-9 in surviving tumour cells. The Journal of Bone and Joint Surgery, British volume, 84, 706–711.

    Article  CAS  Google Scholar 

  120. Vinodhkumar, R., Song, Y. S., Ravikumar, V., Ramakrishnan, G., & Devaki, T. (2007). Depsipeptide a histone deacetylase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). Chemico-Biological Interactions, 165, 220–229.

    Article  PubMed  CAS  Google Scholar 

  121. Shin, C. Y., Lee, W. J., Choi, J. W., Choi, M. S., Ryu, J. R., Oh, S. J., et al. (2007). Down-regulation of matrix metalloproteinase-9 expression by nitric oxide in lipopolysaccharide-stimulated rat primary astrocytes. Nitric Oxide, 16, 425–432.

    Article  PubMed  CAS  Google Scholar 

  122. Kang, H. G., Kim, H. S., Kim, K. J., Oh, J. H., Lee, M. R., Seol, S. M., et al. (2007). RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. Journal of Orthopaedic Research, 25, 696–702.

    Article  PubMed  CAS  Google Scholar 

  123. Takahashi, C., Sheng, Z., Horan, T. P., Kitayama, H., Maki, M., Hitomi, K., et al. (1998). Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proceedings of the National Academy of Sciences of the United States of America, 95, 13221–13226.

    Article  PubMed  CAS  Google Scholar 

  124. Oh, J. H., Takahashi, R., Kondo, S., Mizoguchi, A., Adachi, E., Sasahara, R. M., et al. (2001). The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell, 107, 789–800.

    Article  PubMed  CAS  Google Scholar 

  125. Choong, P. F. M., & Nadesapillai, A. P. W. (2003). Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clinical orthopaedics and related research, 415(Suppl), S46–S58.

    Article  PubMed  Google Scholar 

  126. Choong, P. F. M., Ferno, M., Akerman, M., Willen, H., Langstrom, E., Gustafson, P., et al. (1996). Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. International Journal of Cancer, 69, 268–273.

    Article  CAS  Google Scholar 

  127. Dass, C. R., Nadesapillai, A. P. W., Robin, D., Howard, M. L., Fisher, J. L., Zhou, H., et al. (2005). Downregulation of uPAR cofirms link in growth and metatasis of osteosarcoma. Clinical and Experimental Metastasis, 22, 643–652.

    Article  PubMed  CAS  Google Scholar 

  128. Dass, C. R., & Choong, P. F. M. (2008). uPAR mediates anticancer activity of PEDF. Cancer Biology and Therapy, 7, 1262–1270.

    Article  PubMed  CAS  Google Scholar 

  129. Baldini, N., Scotlandi, K., Serra, M., Picci, P., Bacci, G., Sottili, S., et al. (1999). P-glycoprotein expression in osteosarcoma: a basic for risk-adapted adjuvant chemotherapy. Journal of Orthopaedic Research, 17, 629–632.

    Article  PubMed  CAS  Google Scholar 

  130. Chan, H. S., Grogan, T. M., Haddad, G., DeBoer, G., & Ling, V. (1997). P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. Journal of the National Cancer Institute, 89, 1706–1715.

    Article  PubMed  CAS  Google Scholar 

  131. Laverdiere, C., Hoang, B. H., Yang, R., Sowers, R., Qin, J., Meyers, P. A., et al. (2005). Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clinical Cancer Research, 11, 2561–2567.

    Article  PubMed  CAS  Google Scholar 

  132. Perissinotto, E., Cavalloni, G., Leone, F., Fonsato, V., Mitola, S., Grignani, G., et al. (2005). Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clinical Cancer Research, 11(2 Pt 1), 490–497.

    PubMed  CAS  Google Scholar 

  133. Teodoro, J. G., Evans, S. K., & Green, M. R. (2007). Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. Journal of Molecular Medicine, 85, 1175–1186.

    Article  PubMed  CAS  Google Scholar 

  134. Miller, C. W., Aslo, A., Won, A., Tan, M., Lampkin, B., & Koeffler, H. P. (1996). Alterations of the p53, Rb and MDM2 genes in osteosarcoma. Journal of Cancer Research and Clinical Oncology, 122, 559–565.

    Article  PubMed  CAS  Google Scholar 

  135. McIntyre, J. F., Smith-Sorensen, B., Friend, S. H., Kassel, J., Borresen, A. L., Yan, Y. X., et al. (1994). Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. Journal Clinical Oncology, 12, 925–930.

    CAS  Google Scholar 

  136. Nakase, M., Inui, M., Okumura, K., Kamei, T., Nakamura, S., & Tagawa, T. (2005). p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Molecular Cancer Therapeutics, 4, 625–631.

    Article  PubMed  CAS  Google Scholar 

  137. Densmore, C. L., Kleinerman, E. S., Gautam, A., Jia, S.-F., Xu, B., Worth, L. L., et al. (2001). Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Therapy, 8, 619–627.

    Article  PubMed  CAS  Google Scholar 

  138. Onda, M., Matsuda, S., Higaki, S., Ijima, T., Fukushima, J., Yokokura, A., et al. (1996). ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer, 77, 71–78.

    Article  PubMed  CAS  Google Scholar 

  139. Zhou, H., Randall, R. L., Brothman, A. R., Maxwell, T., Coffin, C. M., & Goldsby, R. E. (2003). Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. Journal of Pediatric Hematology/Oncology, 25, 27–32.

    Article  PubMed  Google Scholar 

  140. US-National-Cancer-Institute. (2001). Phase II Study of Chemotherapy With or Without Trastuzumab (Herceptin®) in Patients With Metastatic Osteosarcoma. http://www.cancer.gov/clinicaltrials/COG-AOST0121. Accessed 30-09 2008.

  141. Hunter, K. W. (2004). Ezrin, a key component in tumor metastasis. Trends in Molecular Medicine, 10, 201–204.

    Article  PubMed  CAS  Google Scholar 

  142. Khanna, C., Wan, X., Bose, S., Cassaday, R., Olomu, O., Mendoza, A., et al. (2004). The membrane-cyto-skeleton linker ezrin is necessary for osteosarcoma metastasis. Nature Medicine, 10, 182–186.

    Article  PubMed  CAS  Google Scholar 

  143. Wan, X., Mendoza, A., Khanna, C., & Helman, L. J. (2005). Rapamycin inhibits ezrin-mediated metastatic behaviour in a murine model of osteosarcoma. Cancer Research, 65, 2406–2411.

    Article  PubMed  CAS  Google Scholar 

  144. Pasquini, G. M., Davey, R. A., Ho, P. W., Michelangeli, V. P., Grill, V., Kaczmarczyk, S. J., & Zajac, J. D. (2002). Local secretion of parathyroid hormone-related protein by an osteoblastic osteosarcoma (UMR 106–01) cell line results in growth inhibition. Bone, 31, 598–605.

    Article  PubMed  CAS  Google Scholar 

  145. Yang, R., Hoang, B. H., Kubo, T., Kawano, H., Chou, A., Sowers, R., et al. (2007). Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. International Journal of Cancer, 121, 943–954.

    Article  CAS  Google Scholar 

  146. Dass, C. R., & Choong, P. F. (2008). C-jun: pharmaceutical target for DNAzyme therapy of multiple pathologies. Pharmazie, 63, 411–414.

    PubMed  CAS  Google Scholar 

  147. Bohmann, D., Bos, T. J., Admon, A., Nishimura, T., Vogt, P. K., & Tjian, R. (1987). Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science, 238, 1386–1392.

    Article  PubMed  CAS  Google Scholar 

  148. Dass, C. R., Khachigian, L. M., & Choong, P. F. M. (2008). c-Jun is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model. Molecular Cancer Research, 6, 1289–1292.

    Article  PubMed  CAS  Google Scholar 

  149. Dass, C. R., Friedhuber, A. M., Khachigian, L. M., Dunstan, D. E., & Choong, P. F. (2008). Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. Cancer biology & therapy, 7, 1033–1036.

    Article  CAS  Google Scholar 

  150. Dass, C. R., Friedhuber, A. M., Khachigian, L. M., Dunstan, D. E., & Choong, P. F. (2008). Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity. Journal of Microencapsulation, 25, 421–425.

    Article  PubMed  CAS  Google Scholar 

  151. Dass, C. R., Khachigian, L. M., & Choong, P. F. M. (2008). c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Molecular Cancer Therapeutics, 7, 1909–1912.

    Article  PubMed  CAS  Google Scholar 

  152. MacEwen, E. G., Pastor, J., Kutzke, J., Tsan, R., Kurzman, I. D., Thamm, D. H., et al. (2004). IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. Journal of Cellular Biochemistry, 92, 77–91.

    Article  PubMed  CAS  Google Scholar 

  153. Sekyi-Otu, A., Bell, R. S., Ohashi, C., Pollak, M., & Andrulis, I. L. (1995). Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Research, 55, 129–134.

    PubMed  CAS  Google Scholar 

  154. Pollak, M., Sem, A. W., Richard, M., Tetenes, E., & Bell, R. (1992). Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. Journal of the National Cancer Institute, 84, 966–971.

    Article  PubMed  CAS  Google Scholar 

  155. Burrow, S., Andrulis, I. L., Pollak, M., & Bell, R. S. (1998). Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. Journal of Surgical Oncology, 69, 21–27.

    Article  PubMed  CAS  Google Scholar 

  156. Frincu-Mallos, C. (2007). Novel anti-IGF-1 receptor drug, R1507, shows potential in sarcoma patients. http://www.pslgroup.com/dg/216426.htm. Accessed 30/09 2008.

  157. Pollak, M., Sem, A. W., Richard, M., Tetenes, E., & Bell, R. (1992). Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. Journal of the National Cancer Institute, 84, 966–971.

    Article  PubMed  CAS  Google Scholar 

  158. Mansky, P. J., Liewehr, D. J., Steinberg, S. M., Chrousos, G. P., Avila, N. A., Long, L., et al. (2002). Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. Journal of Pediatric Hematology/Oncology, 24, 440–446.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemical and Biomolecular Engineering, University of Melbourne, Melbourne, VIC, 3010, Australia

    Hang T. Ta & Dave E. Dunstan

  2. Departments of Orthopaedics and Surgery, St Vincent’s Hospital Melbourne, Melbourne, VIC, 3065, Australia

    Crispin R. Dass & Peter F. M. Choong

  3. Sarcoma Service, Peter MacCallum Cancer Centre, Melbourne, VIC, 3002, Australia

    Peter F. M. Choong

Authors
  1. Hang T. Ta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Crispin R. Dass
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter F. M. Choong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dave E. Dunstan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Crispin R. Dass.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ta, H.T., Dass, C.R., Choong, P.F.M. et al. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 28, 247–263 (2009). https://doi.org/10.1007/s10555-009-9186-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-009-9186-7

Keywords

Search

Navigation